GLP-1 Receptor Agonists
Revolutionize Cardiovascular
& Kidney Protection:
How SELECT & FLOW Trials
Reshaped Diabetes Care
The history of diabetes treatment has reached an inflection point. For decades, the central question in managing type 2 diabetes (T2D) was: How low should we push the blood sugar? But two landmark clinical trials published in 2023 and 2024 have fundamentally changed that question. The medical community is now asking: How do we protect the heart and kidneys?
GLP-1 receptor agonists (GLP-1 RAs) were originally developed to lower blood glucose in T2D through a combination of mechanisms: stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. The class includes semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and dulaglutide (Trulicity), among others. Semaglutide — already globally recognized under both its Ozempic and Wegovy brand names — is the protagonist of both pivotal trials discussed here.
What if this drug class could do far more than control blood sugar — cutting cardiovascular death, heart attack, and stroke by 20%, and slowing the progression of chronic kidney disease by 24%? That is precisely the message delivered by the SELECT and FLOW trials, both published in the New England Journal of Medicine, the world's highest-impact medical journal. The American Diabetes Association (ADA) moved swiftly, incorporating these findings directly into its 2025 Standards of Medical Care.
This article provides a rigorous, data-driven analysis of both trials — their design, results, mechanistic implications, and real-world clinical impact. All data presented are drawn directly from the published primary sources. This content is for educational purposes only; all treatment decisions must be made in consultation with a qualified healthcare provider.
PART 1 · The SELECT Trial — A Cardiovascular Revolution Beyond Diabetes
1-1. What Is the SELECT Trial?
The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a large-scale, randomized, double-blind, placebo-controlled trial designed to evaluate the cardiovascular effects of subcutaneous semaglutide 2.4 mg weekly. Its most striking feature is that it enrolled adults with overweight or obesity who had established cardiovascular disease but no diabetes — a population previously unexplored in GLP-1 RA cardiovascular outcome trials.
Source: Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med 2023;389(24):2221-2232.
Population: Overweight/obese adults (BMI ≥27) with established cardiovascular disease — 17,604 participants (no diabetes)
Intervention: Semaglutide 2.4 mg SC weekly vs. placebo | Follow-up: Median 34.2 months
HR 0.80 (95% CI 0.72–0.90), p<0.001
Primary Outcome: Composite of cardiovascular death + nonfatal myocardial infarction + nonfatal stroke — 20% reduction
Body Weight Change: Semaglutide group −9.4% vs. placebo −0.9%
1-2. Study Design: Why These Results Carry Exceptional Weight
The SELECT trial is not merely large in sample size — it is rigorous in design. With 17,604 participants enrolled across 804 sites in 45 countries, it ranks among the largest cardiovascular outcome trials (CVOTs) ever conducted. The double-blind, placebo-controlled design minimizes bias, and the multinational, multi-ethnic cohort strengthens generalizability across diverse populations.
The primary endpoint — 3-point MACE (Major Adverse Cardiovascular Events) — is the gold standard composite endpoint in cardiovascular medicine, encompassing: (1) cardiovascular death, (2) nonfatal myocardial infarction, and (3) nonfatal stroke. A hazard ratio of 0.80 means that participants receiving semaglutide were 20% less likely to experience one of these three events compared to the placebo group. The 95% confidence interval of 0.72–0.90 lies entirely below 1.0, confirming strong statistical significance with a p-value below 0.001.
To put this in perspective: the number needed to treat (NNT) over approximately 3 years was in a clinically meaningful range, representing a substantial absolute reduction in one of the most serious and costly complications a clinician deals with — a cardiovascular event in a high-risk patient.
1-3. The Mechanistic Question: Why Does Semaglutide Protect the Heart Without Lowering Blood Sugar?
The deepest scientific implication of SELECT is the strong suggestion that cardiovascular protection by GLP-1 RAs operates independently of glycemic lowering. Because all participants were non-diabetic, the conventional explanation — "lower blood sugar, protect the heart" — cannot fully account for the observed 20% MACE reduction. Several plausible mechanisms have been proposed:
Systemic Anti-Inflammatory Effects
GLP-1 RAs suppress pro-inflammatory cytokines (IL-6, TNF-α) in vascular endothelial cells and macrophages. In SELECT, high-sensitivity CRP was significantly reduced in the semaglutide group vs. placebo, indicating meaningful systemic inflammation suppression.
Central Appetite & Sympathetic Regulation
GLP-1 RAs act on hypothalamic GLP-1 receptors to reduce appetite and modulate sympathetic nervous system tone. The resulting 9.4% body weight loss and modest blood pressure reduction likely contributed to MACE reduction in a multifactorial manner.
Atherosclerotic Plaque Stabilization
Preclinical data show that GLP-1 RAs reduce macrophage infiltration into atherosclerotic plaques and increase fibrous cap thickness, thereby stabilizing vulnerable plaques and reducing the risk of rupture-triggered acute coronary events.
Direct Cardiomyocyte Protection
GLP-1 receptors are expressed on cardiomyocytes, and preclinical studies indicate that GLP-1 RAs can reduce apoptosis (programmed cell death) during myocardial ischemia, suggesting a direct cardiac protective mechanism beyond metabolic effects.
SELECT investigators conducted a mediation analysis demonstrating that while weight loss partially mediates the cardiovascular benefit, a significant residual benefit persists even after statistical adjustment for body weight changes — reinforcing the hypothesis of weight-independent cardioprotective mechanisms.
1-4. Historical Significance: From Weight Loss Drug to Cardiovascular Therapy
Before SELECT, the prevailing narrative around obesity medications was centered on aesthetics and metabolic risk factor management. SELECT redefined the conversation entirely: it provided the first large-scale RCT evidence that a pharmacological treatment for obesity can function as a secondary prevention cardiovascular agent — protecting patients who have already had a cardiovascular event from having another one. This is not a subtle distinction. It is a category shift that places semaglutide alongside statins and ACE inhibitors as a genuine cardiovascular therapeutic.
PART 2 · The FLOW Trial — Rewriting the Standard of Care for Diabetic Kidney Disease
2-1. The Burden of Diabetic Kidney Disease
Diabetes is the leading cause of chronic kidney disease (CKD) worldwide, responsible for approximately 40% of end-stage renal disease (ESRD) requiring dialysis or kidney transplantation. Diabetic nephropathy develops in 20–40% of people with T2D through sustained hyperglycemia-driven mechanisms: elevated intraglomerular pressure, oxidative stress, and chronic inflammation that progressively destroy glomerular architecture. The annual rate of eGFR decline serves as the critical prognostic indicator — the faster it falls, the sooner a patient reaches the threshold for renal replacement therapy.
Prior to FLOW, SGLT2 inhibitors (empagliflozin via EMPA-KIDNEY, dapagliflozin via DAPA-CKD) had already demonstrated kidney protection in CKD patients. However, FLOW was the first prospective trial to designate a kidney composite outcome as its primary endpoint for a GLP-1 RA — a distinction that makes this trial uniquely definitive.
Source: Perkovic V et al. "Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease." N Engl J Med 2024;391(18):1757-1769.
Population: Adults with T2D and CKD — 3,533 participants
Intervention: Semaglutide 1.0 mg SC weekly vs. placebo
HR 0.76 (95% CI 0.66–0.88), p<0.001
Primary Outcome: Composite of kidney disease progression (≥50% sustained eGFR reduction or eGFR <15) + death from kidney failure + cardiovascular death — 24% reduction
2-2. The eGFR Decline Rate: The Most Critical Kidney Protection Metric
One of the most clinically compelling findings from FLOW was the impact of semaglutide on the annual rate of eGFR decline. The eGFR (estimated glomerular filtration rate, measured in mL/min/1.73m²) quantifies the kidneys' filtering capacity per minute — the lower and faster it falls, the sooner a patient may require dialysis or transplantation.
The placebo group lost eGFR at a rate of −3.85 mL/min/1.73m² per year, while the semaglutide group declined at only −2.19 mL/min/1.73m² per year — a preserved difference of approximately 1.66 mL/min/1.73m²/year. When compounded over years, this difference translates into substantially more functioning kidney tissue retained, delayed dialysis initiation, and improved quality of life. For a patient starting with an eGFR of 40, the divergence in projected kidney function over a decade is clinically profound.
2-3. Early Termination: An Unambiguous Signal of Benefit
The FLOW trial was terminated early by its independent Data Safety Monitoring Board (DSMB) after an interim analysis revealed that the benefit in the semaglutide arm had crossed the pre-specified threshold for early stopping due to efficacy. In clinical trial ethics, continuing to randomize patients to a placebo arm when an intervention demonstrates overwhelming benefit becomes unjustifiable. Early termination in FLOW signals not a flaw in the data, but the opposite — a benefit so clear and consistent that the trial had answered its primary question ahead of schedule. This is one of the strongest signals of robustness in randomized trial methodology.
2-4. Kidney Protection Mechanisms: Beyond Blood Sugar
The FLOW investigators similarly noted that semaglutide's renoprotective effects appeared to exceed what could be explained by blood glucose and blood pressure reductions alone. The proposed kidney-specific mechanisms include:
Reduction in Intraglomerular Pressure
GLP-1 RAs dilate the afferent arteriole, reducing intraglomerular hyperfiltration — a key driver of glomerular damage in diabetic nephropathy. This hemodynamic protection is structurally analogous to the mechanism by which SGLT2 inhibitors protect the kidney.
Renal Anti-Inflammatory & Anti-Fibrotic Effects
GLP-1 RAs suppress NF-κB pathway signaling in renal tubular epithelial cells and kidney-resident macrophages, reducing chronic interstitial inflammation and fibrosis — the primary drivers of irreversible nephron loss in CKD.
Albuminuria Reduction
In FLOW, the semaglutide group showed a significantly greater reduction in urinary albumin-to-creatinine ratio (UACR) vs. placebo. Since albuminuria is both a biomarker and a mediator of glomerular injury, this reduction directly reflects nephron protection.
Combined Hemodynamic Benefit
Semaglutide-induced body weight loss and systolic blood pressure reduction (approximately −3 to −4 mmHg) improve overall renal perfusion dynamics, contributing an additional layer of kidney protection beyond the drug's direct molecular effects.
PART 3 · ADA 2025 Standards of Care — A Fundamental Shift in Treatment Algorithms
3-1. The Old Paradigm: "Glucose First, Organs Later"
Until the early 2010s, the logic of diabetes treatment algorithms was straightforward: Step 1, start metformin. Step 2, add agents if glycemic targets are not met. Cardiovascular disease and kidney disease were managed as separate problems — antihypertensives, statins, and ACE inhibitors worked in parallel tracks. The idea that a glucose-lowering agent could simultaneously and substantially protect the heart and kidneys was, at best, a hypothesis.
That paradigm began fracturing with the 2015 EMPA-REG OUTCOME trial (empagliflozin), then accelerated through LEADER (liraglutide), SUSTAIN-6 (semaglutide), CREDENCE (canagliflozin kidney protection), DAPA-HF (dapagliflozin heart failure), and DECLARE-TIMI 58 (dapagliflozin). The SELECT and FLOW trials delivered the final transformation — placing GLP-1 RAs as primary organ-protective agents independent of glycemic status.
3-2. ADA 2025: GLP-1 RAs as First-Line Agents, Independent of Metformin
📋 ADA 2025 Standards of Medical Care — Core Recommendation
Source: American Diabetes Association. "Standards of Care in Diabetes—2025." Diabetes Care 2025;48(Supplement 1).
Key Recommendation: In patients with T2D and established cardiovascular disease or chronic kidney disease, a GLP-1 receptor agonist or SGLT2 inhibitor is recommended as a first-line pharmacological agent, independent of metformin use or baseline HbA1c.
This represents an explicit paradigm shift: from "metformin first, cardiovascular/renal protection later" to "if cardiovascular or kidney risk is present, prioritize GLP-1 RA or SGLT2i from the outset." It elevates these drug classes from glucose-lowering agents to organ-protective therapeutics.
The clinical impact of this recommendation is far-reaching. A substantial proportion of people with T2D globally have co-existing cardiovascular disease or CKD, meaning the population for whom GLP-1 RAs and SGLT2 inhibitors are now first-line agents is enormous. Equally important, the recommendation explicitly removes the requirement for metformin as a prerequisite — which is clinically critical for patients with advanced CKD where metformin is contraindicated.
3-3. GLP-1 RA vs. SGLT2 Inhibitor: Navigating the Choice
When both GLP-1 RAs and SGLT2 inhibitors are indicated, the 2025 ADA framework offers nuanced guidance. In patients where atherosclerotic cardiovascular disease (ASCVD) predominates, or where significant weight loss is a clinical goal, GLP-1 RAs tend to be favored. When heart failure or more advanced CKD (eGFR 20–45) is the dominant concern, SGLT2 inhibitors have an edge. Because the two classes act through distinct and complementary mechanisms, combination therapy is increasingly supported by data and clinical practice guidelines — though this decision requires careful individual assessment by a specialist.
| Category | SELECT Trial (2023) | FLOW Trial (2024) |
|---|---|---|
| Drug / Dose | Semaglutide 2.4 mg/week SC | Semaglutide 1.0 mg/week SC |
| Population | Overweight/obese + established CVD (no diabetes) | T2D + chronic kidney disease (CKD) |
| Sample Size | 17,604 participants | 3,533 participants |
| Follow-up | Median 34.2 months | Early termination (clear efficacy) |
| Primary Endpoint | 3-point MACE (CV death, MI, stroke) | Kidney composite (progression, CV death, renal death) |
| Risk Reduction | 20% reduction (HR 0.80) | 24% reduction (HR 0.76) |
| 95% CI | 0.72–0.90 | 0.66–0.88 |
| p-value | p < 0.001 | p < 0.001 |
| Journal | NEJM 2023;389(24) | NEJM 2024;391(18) |
3-4. Safety Profile: Managing Risk Alongside Benefit
The predominant adverse effects of GLP-1 RAs are gastrointestinal (GI): nausea, vomiting, diarrhea, and constipation. These are most pronounced during dose titration and typically diminish over weeks. In SELECT, nausea was reported in over 10% of participants in the semaglutide arm but was mostly mild-to-moderate and self-limiting. Rates of treatment discontinuation due to GI adverse events were relatively low.
In FLOW, there was no statistically significant difference in serious adverse event rates between the semaglutide and placebo groups. Theoretical concerns about pancreatitis and medullary thyroid carcinoma (based largely on rodent data) have not been confirmed as elevated risks in large-scale human trials to date. Nonetheless, these considerations warrant open discussion between patients and clinicians at the time of prescribing. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use GLP-1 RAs.
Six Evidence-Based Practice Points for Patients and Clinicians
- T2D patients with established cardiovascular disease: Per ADA 2025, a GLP-1 RA or SGLT2 inhibitor should be considered first-line regardless of metformin use. Consult your specialist to determine which agent best fits your clinical profile, kidney function, and individual risk factors.
- T2D patients with CKD: FLOW data demonstrate that semaglutide 1.0 mg/week significantly preserves kidney function (eGFR −2.19 vs. −3.85 mL/min/1.73m²/year). Discuss GLP-1 RA initiation with your nephrologist or endocrinologist, especially if metformin is contraindicated due to low eGFR.
- Non-diabetic patients with obesity and CVD: SELECT established that semaglutide 2.4 mg/week reduces MACE by 20% in non-diabetic patients. Approval status varies by country and indication — consult a cardiologist or endocrinologist about whether this applies to your clinical situation.
- Managing GI side effects: Nausea and vomiting are most common in the first 4–8 weeks. Starting at a low dose and titrating gradually, eating smaller and lower-fat meals, and avoiding alcohol can all help minimize symptoms. If GI symptoms are severe or persistent, notify your physician — do not adjust dosing independently.
- Regular monitoring while on therapy: Even during GLP-1 RA treatment, periodic monitoring of eGFR, urinary albumin-to-creatinine ratio (UACR), blood pressure, and HbA1c remains essential. Monitoring enables early detection of both treatment response and potential adverse effects and should be guided by your healthcare team.
- Lifestyle modification remains indispensable: GLP-1 RAs are powerful but not a substitute for dietary improvement, regular physical activity, smoking cessation, and adequate sleep. The cardio-renal benefits seen in SELECT and FLOW were observed in the context of ongoing guideline-directed medical care — lifestyle optimization amplifies pharmacological benefit. Always consult your physician before making changes to your treatment plan.
References and Data Sources
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563
- Perkovic V, Tuttle KR, Rossing P, et al. "Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease." N Engl J Med. 2024;391(18):1757-1769. https://doi.org/10.1056/NEJMoa2403317
- American Diabetes Association Professional Practice Committee. "Standards of Care in Diabetes—2025." Diabetes Care. 2025;48(Supplement 1):S1-S352. https://doi.org/10.2337/dc25-SINT
- Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)." N Engl J Med. 2016;375(4):311-322. https://doi.org/10.1056/NEJMoa1603827
- Zinman B, Wanner C, Lachin JM, et al. "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)." N Engl J Med. 2015;373(22):2117-2128. https://doi.org/10.1056/NEJMoa1504720
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. "Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)." N Engl J Med. 2020;383(15):1436-1446. https://doi.org/10.1056/NEJMoa2024816
- Husain M, Birkenfeld AL, Donsmark M, et al. "Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6)." N Engl J Med. 2019;381(9):841-851. https://doi.org/10.1056/NEJMoa1901118
Frequently Asked Questions (FAQ)
Can semaglutide be prescribed for cardiovascular protection even without a diabetes diagnosis?
SELECT demonstrated a 20% MACE reduction in non-diabetic patients, but prescribing eligibility depends on regulatory approval in each country. In the U.S., Wegovy (semaglutide 2.4 mg) received FDA approval for cardiovascular risk reduction in adults with obesity or overweight and established CVD in March 2024, informed directly by the SELECT data. In other countries, approval status varies — consult your cardiologist or endocrinologist to determine whether this indication applies to your situation. This is a clinical decision that must involve a qualified physician.
Can GLP-1 RAs and SGLT2 inhibitors be used together safely?
Both drug classes protect the heart and kidneys through different and complementary mechanisms, providing a strong biological rationale for combination therapy. Combination use is practiced clinically and is increasingly supported by guidelines. However, potential overlapping risks — including hypotension, volume depletion, and urinary tract infections — require careful monitoring of blood pressure, electrolytes, and kidney function. The decision to combine these agents should be made with your specialist, who can assess your individual risk-benefit profile.
At what stage of CKD is semaglutide most beneficial, according to FLOW?
The FLOW trial enrolled patients with eGFR in the range of 25–75 mL/min/1.73m² and albuminuria (UACR ≥300 mg/g or higher). Kidney benefits were most pronounced in patients with higher levels of albuminuria, suggesting that patients with active glomerular inflammation and damage derive the greatest benefit. Patients with very advanced CKD (eGFR <15, end-stage renal disease) were excluded from FLOW, so evidence in that population remains limited. Your nephrologist is best positioned to advise you based on your specific eGFR and urine albumin values.
How long does it take before cardiovascular and kidney benefits become apparent?
In the SELECT and FLOW trials, Kaplan-Meier event curves began diverging meaningfully within the first 6–12 months of treatment. However, the full magnitude of the benefit — particularly for kidney protection — accumulates progressively over years of continued therapy. This underscores the importance of long-term adherence: stopping the medication reverses the sustained benefit that depends on continuous pharmacological engagement. Your physician will help you determine treatment duration based on your individual clinical trajectory.